Efficacy and safety of repaglinide in the treatment of severe newly diagnosed type 2 diabetic patients

AIM To investigate the efficacy and safety of repaglinide therapy in newly diagnosed type 2 diabetic patients with HbA1c8.5%.METHODS Forty-six newly diagnosed type 2 diabetic patients were divided into 2 groups randomly.The combined group(23 patients) was given combined repaglinide and metformin orally.The monotherapy group(23 patients) was given repaglinide orally.After treatment for 16 weeks,the HbA1c,fasting blood glucose(FBG), postprandial 2 h blood glucose(PBG),weight,adverse drug reactions and hypoglycemic episodes were observed in both groups.RESULTS After the therapy with repaglinide,the weight wasn' t increased(P0.05),the level of FBG was decreased by 2.8 mmol·L~(-1)(P0.01),PBG was decreased by 5.2 mmol·L~(-1)(P0.01),and HbA1c was decreased by3.9%(P0.01).The attainment rate of HbA1c was 81.8%.The glucose was improved in both groups after the therapy,the weight wasn't increased.The control rate of HbA1c was 81.8%.The combined group was more effient than the monotherapy group,but the difference was not significant(P0.05).The control rate of HbA1c was comparative. CONCLUSION In newly diagnosed type 2 diabetic patients with HbA1c8.5%,repaglinide therapy,whether or not combined with metformin,can safely and efficiently decrease HbA1c,FBG and PBG,especially PBG.The repaglinide therapy combined with metformin can decrease the dose of repaglinide.